MK-677 Half-Life and Pharmacokinetics: What Studies Report

What "pharmacokinetics" and "half-life" describe

Pharmacokinetics covers what a body does to an administered compound: absorption, distribution, metabolism and excretion. Half-life is one derived parameter inside that framework — the time required for the plasma concentration of a compound to fall by half during the elimination phase. It is not the same as a detection window (how long analytical methods can find a parent compound or its metabolites in a matrix such as urine or hair), and it is not the same as the duration of a biological effect, since downstream hormonal responses can outlast measurable drug concentrations.

MK-677 — also written ibutamoren or MK-0677 — is an orally active, non-peptide growth hormone secretagogue. This page summarises only what the verified papers listed in the references reported, organised by species and route, and flags explicitly where those papers contain no pharmacokinetic parameters at all. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or laboratory testing.

Human data: what the verified literature does and does not report

The largest human study in this set was a randomised, placebo-controlled trial in mild-to-moderate Alzheimer's disease. Researchers administered oral MK-677 at 25 mg daily, or matching placebo, for 12 months, and the study reported that the secretagogue did not slow progression of the disease on the primary cognitive and global outcomes. That trial also reported increases in circulating IGF-1 with the active treatment, consistent with sustained stimulation of the growth hormone axis over the treatment period (Neurology, 2008).

What that publication did not contain is a pharmacokinetic dataset. No terminal half-life, no time to maximum concentration, no volume of distribution, no plasma clearance, no bioavailability estimate and no metabolite profile in humans appeared in its reported scope. The only structural pharmacokinetic information that can be drawn from it is descriptive: the trial used a single oral tablet taken once per day, and that schedule was maintained for a year (Neurology, 2008). A once-daily oral schedule is the administration design the investigators chose; it is not itself a measured half-life, and no half-life figure should be inferred from it.

This is the central gap for anyone searching for human elimination data: within the verified literature reviewed on this page, human pharmacokinetic parameters for MK-677 are absent. Statements circulating in non-scientific sources about a specific number of hours of persistence in the human body do not trace back to any of the papers summarised here.

Route studied: oral in every verified paper

Every administration route described in the verified set was oral. The human trial used daily oral administration (Neurology, 2008), the equine metabolism work used oral administration (Drug Testing and Analysis, 2022), the equine hair study used oral administration (Drug Testing and Analysis, 2023), and the rat investigation examined an orally active secretagogue (Yonsei Medical Journal, 2018). No injectable, transdermal, sublingual or intranasal pharmacokinetic comparison appears in this literature set, so no route-to-route comparison can be made from it.

Equine studies: the most detailed metabolic and detection work

Plasma and urine

The most granular ADME-type information in the verified set came from horses, driven by anti-doping analytical needs rather than therapeutic development. Researchers investigated equine metabolism of MK-0677 in vitro and then in urine and plasma collected after oral administration, and the study reported the identification of metabolites that could serve as analytical targets alongside the parent compound. The in vitro phase used equine liver preparations to predict biotransformation products, which were then sought in post-administration samples (Drug Testing and Analysis, 2022).

Two points follow from that design. First, MK-0677 undergoes hepatic biotransformation in the horse, producing metabolites recoverable in excreted urine — the compound is not simply eliminated unchanged. Second, urinary metabolite targets were pursued specifically because they can extend an analytical detection window beyond that of the parent compound. Detection windows in anti-doping science depend on assay sensitivity, sampling frequency, dose and matrix, and they are therefore not interchangeable with a pharmacokinetic half-life.

Hair

A separate equine investigation examined hair as a matrix and reported detection of MK-0677 in equine hair following oral administration. Keratinised matrices such as hair incorporate compounds from the circulation during growth, which is why they are used for retrospective, long-window screening in both equine and human forensic toxicology. Detection in hair reflects historical exposure recorded in a growing fibre, not ongoing circulating concentrations, and the researchers framed the work as an analytical tool for demonstrating prior administration (Drug Testing and Analysis, 2023).

Because equine hepatic metabolism, body composition and hair growth rates differ from those of humans, these findings describe the horse. They do not translate directly into human clearance rates or human testing windows, and neither paper claimed that they did.

Rodent data: growth outcomes rather than kinetics

The rodent paper in this set examined the effect of the orally active growth hormone secretagogue MK-677 on somatic growth in rats (Yonsei Medical Journal, 2018). Its stated focus was growth outcomes in a rat model rather than plasma concentration–time curves, so it contributes evidence of oral activity in a rodent species but no absorption, distribution or elimination parameters. Researchers designing such a study generally select dosing frequency from prior work in the species; the published account summarised here reported on growth, not on kinetics.

What each verified study contributes

Human case reports: outcomes without concentration data

Two human case reports appear in the verified set, and neither measured drug concentrations. In one, researchers documented an individual who used LGD-4033 together with MK-677 and reported changes in body composition, circulating biomarkers and skeletal muscle androgenic hormone and receptor content. Because two compounds were taken concurrently and the report described a single person, the design cannot attribute any individual finding to MK-677 alone, and it contains no plasma pharmacokinetic sampling (Experimental Physiology, 2022).

Hepatic and safety observations: What Studies Report

A 2025 case report described hepatotoxicity in association with MK-677 use (BMJ Case Reports, 2025). A single case report establishes temporal association in one person rather than causation or incidence, but it is relevant to a pharmacokinetics discussion for one reason: the liver is a principal site of biotransformation, and the equine work independently demonstrated hepatic metabolism of the compound to multiple products (Drug Testing and Analysis, 2022). Whether hepatic handling differs between species, or between individuals, was not resolved by any paper in this set.

On the longer-term human side, the year-long randomised trial monitored participants receiving daily oral MK-677 at 25 mg for 12 months and reported that the compound did not produce a clinical benefit on Alzheimer's disease progression. That trial remains the longest controlled human exposure in the verified set, and its safety monitoring is the largest systematically collected human dataset available here (Neurology, 2008).

Why detection windows and half-life are frequently conflated

Search interest around how long MK-677 remains measurable usually blends three distinct concepts:

• Elimination half-life — a plasma concentration parameter, absent for humans in this literature set.
• Analytical detection window — dependent on assay sensitivity, matrix and metabolite targets; characterised in horses for urine, plasma and hair (Drug Testing and Analysis, 2022) and (Drug Testing and Analysis, 2023).
• Duration of pharmacodynamic effect — for a secretagogue, the hormonal response can persist on a different timescale from drug concentration; the human trial tracked IGF-1 across 12 months of daily oral dosing (Neurology, 2008).

These three quantities can differ by orders of magnitude for the same compound, which is why a hair-detection finding in a horse says nothing directly about plasma persistence in a person.

Limitations of this evidence base

1. No human ADME study is present in the verified set; there is no human half-life, Cmax, Tmax, clearance or bioavailability figure to report.
2. Species mismatch. The detailed metabolic characterisation was equine, performed for regulatory testing purposes (Drug Testing and Analysis, 2022).
3. Single-route evidence. All administration described was oral.
4. Case reports are uncontrolled. One involved concurrent use of a second compound (Experimental Physiology, 2022), and the hepatotoxicity account describes one patient (BMJ Case Reports, 2025).
5. Regulatory status. MK-677 is not an approved medicine; material labelled for research use only is not intended for human consumption.

Where a page like this would normally present a table of pharmacokinetic constants, the honest summary is that the verified human literature does not supply them. Readers evaluating claims about persistence, washout or testing timelines can check whether the source cites a human pharmacokinetic study at all, or whether it is extrapolating from animal analytical work.

References

• Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (Neurology, 2008)
• Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration (Drug Testing and Analysis, 2022)
• Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration (Drug Testing and Analysis, 2023)
• Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats (Yonsei Medical Journal, 2018)
• LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report (Experimental Physiology, 2022)
• Hepatotoxicity induced by MK-677 (BMJ Case Reports, 2025)